Alopecia - Pipeline Insight, 2024

Alopecia - Pipeline Insight, 2024

DelveInsight’s, “Alopecia - Pipeline Insight, 2024” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Alopecia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Alopecia: Understanding

Alopecia: Overview

Alopecia is a condition that causes hair loss, either in localized patches or across the entire scalp and body. It can affect people of all ages and genders, with varying degrees of severity. The most common forms include alopecia areata, an autoimmune disorder that leads to patchy hair loss, and androgenetic alopecia, commonly known as male or female pattern baldness. Alopecia can be triggered by a range of factors, including genetics, hormonal changes, autoimmune diseases, stress, or certain medical treatments. The signs and symptoms of alopecia vary depending on the type and severity of hair loss. In alopecia areata, the most common symptom is patchy hair loss, where small, round, smooth bald spots develop on the scalp or other areas of the body. In androgenetic alopecia, hair thinning occurs gradually, often starting at the temples or crown for men, while women may experience diffuse thinning across the scalp. Some people may also notice increased hair shedding, often seen during brushing or washing. In rare cases, complete loss of scalp hair (alopecia totalis) or body hair (alopecia universalis) can occur.

The pathology of alopecia varies depending on its type, but it generally involves disruptions in the normal hair growth cycle. In alopecia areata, an autoimmune response leads to the body’s immune system mistakenly attacking hair follicles, causing them to shrink and stop producing hair. This results in patchy hair loss, and in severe cases, more widespread hair loss. In androgenetic alopecia, the primary cause is a genetic sensitivity to dihydrotestosterone (DHT), a hormone that causes hair follicles to gradually shrink, leading to thinner, shorter hairs and eventual baldness.

The diagnosis of alopecia typically involves a thorough medical history, physical examination, and, in some cases, additional tests to determine the underlying cause of hair loss. During the physical exam, a dermatologist inspects the pattern of hair loss, the condition of the scalp, and may perform a ""pull test"" to assess the extent of shedding. If autoimmune or genetic factors are suspected, blood tests may be conducted to check for conditions like thyroid dysfunction or hormonal imbalances. A scalp biopsy may also be performed to examine the hair follicles under a microscope, helping to distinguish between different types of alopecia. The treatment of alopecia depends on its type and severity. For alopecia areata, corticosteroid injections or topical treatments are often used to suppress the immune response and promote hair regrowth. Minoxidil (Rogaine) is a widely used over-the-counter medication that helps stimulate hair growth in androgenetic alopecia, while finasteride (Propecia), a prescription oral medication, works by reducing dihydrotestosterone (DHT) levels in men.

""Alopecia- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alopecia pipeline landscape is provided which includes the disease overview and Alopecia treatment guidelines. The assessment part of the report embraces, in depth Alopecia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alopecia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Alopecia R&D. The therapies under development are focused on novel approaches to treat/improve Alopecia.

Alopecia Emerging Drugs Chapters

This segment of the Alopecia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Alopecia Emerging Drugs

Clascoterone: Cosmo Pharmaceuticals

Clascoterone, marketed under the name Breezula, is a topical androgen receptor inhibitor currently being studied for the treatment of androgenetic alopecia (AGA). Clascoterone functions by inhibiting the binding of dihydrotestosterone (DHT) and testosterone to androgen receptors in the scalp. This action is crucial because DHT is a primary factor in the miniaturization of hair follicles associated with AGA. By blocking these hormones from attaching to their receptors, clascoterone aims to halt hair loss and promote new hair growth. Currently, the drug is in the Phase III stage of its development for the treatment of AGA.

ADX-914: Q32 Bio Inc.

ADX-914, now known as Bempikibart, is a fully human anti-IL-7Rα antibody developed by Q32 Bio Inc. in collaboration with Horizon Therapeutics. This therapeutic agent aims to re-regulate adaptive immune function by blocking signaling pathways mediated by interleukin-7 (IL-7) and thymic stromal lymphopoietin (TSLP), both of which are implicated in various autoimmune conditions. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Alopecia.

SCO 240: SCOHIA PHARMA

SCO-240, developed by SCOHIA PHARMA, is an orally administered antagonist of somatostatin receptor type 5 (SSTR5). Although primarily investigated for its potential in treating growth hormone-related disorders, recent studies have explored its broader therapeutic applications, including implications for alopecia. SCO-240 functions by antagonizing SSTR5, which plays a role in regulating endocrine and exocrine secretions. This antagonism has been shown to stimulate growth hormone (GH) secretion without affecting other pituitary hormones, indicating a targeted action that may have various therapeutic implications. Currently, the drug is in the Phase I stage of development to treat Alopecia.

Further product details are provided in the report……..

Alopecia: Therapeutic Assessment

This segment of the report provides insights about the different Alopecia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Alopecia

There are approx. 18+ key companies which are developing the therapies for Alopecia. The companies which have their Alopecia drug candidates in the most advanced stage, i.e. Phase III include, Cosmo Pharmaceuticals.

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Alopecia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Alopecia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alopecia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alopecia drugs.

Alopecia Report Insights

Alopecia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Alopecia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Alopecia drugs?

How many Alopecia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alopecia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alopecia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Alopecia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Cosmo Pharmaceuticals

Suzhou Kintor Pharmaceuticals

Q32 Bio Inc.

SCOHIA PHARMA

Arcutis Biotherapeutics

Aranda Pharma

JW Pharmaceutical

Key Products

Clascoterone

KX0826

ADX-914

GT 20029

SCO 240

ARQ-255

ADA 308

JW 0061